What specific blood tests should I run before starting an LGD-4033 cycle?

Run a full hormonal baseline: total testosterone, LH, FSH, SHBG, and estradiol. Add a lipid panel (HDL, LDL, triglycerides) and a hepatic enzyme panel (ALT, AST, bilirubin). These six categories provide the reference values needed to interpret every subsequent mid-cycle and post-cycle draw against your own physiology rather than population averages.

How much does HDL typically drop during an LGD-4033 cycle and when does it recover?

Clinical and user-reported data consistently show HDL suppression in the 20–30% range on LGD-4033, detectable by week 3–4 of dosing. Recovery typically begins within 4–6 weeks after the final dose, though the timeline depends on cycle length and individual lipid metabolism. A mid-cycle lipid panel at week 4 provides the earliest actionable signal.

Is LGD-4033 hepatotoxic, and do I need to monitor liver enzymes during a cycle?

LGD-4033 is not a methylated compound and shows a substantially lower hepatotoxic profile compared to 17-alpha-alkylated oral steroids. However, Phase I trial data (Basaria et al., 2013) did record mild transient ALT fluctuations in some subjects. Monitoring ALT and AST at baseline and mid-cycle remains the only objective method to confirm your individual hepatic response.

Why choose 10mg/tab for a lab-monitored LGD-4033 cycle rather than a higher concentration tablet?

The 10 mg tablet is the entry-level concentration in this product group, giving you precise dose control at the 5 mg (half-tablet) and 10 mg increments most commonly used during monitored protocols. When bloodwork signals mid-cycle adjustment — such as a significant HDL drop — a lower unit dose lets you step down without switching products.

How should I store Master Pharma Ligandrol 10mg tablets, and does storage affect dose accuracy?

Store tablets at room temperature (15–25 °C), away from direct light and humidity. Blistered tablet formats are inherently more stable than open-bottle storage. Master Pharma's HPLC-verified active-content data applies to properly stored units; temperature or humidity excursions can degrade potency and introduce variance that invalidates dose-tracking against your bloodwork timeline. (2) angle_used

Top Seller

Master Pharma

Ligandrol (LGD-4033) 10mg/tab 60 Tablets by Master Pharma

Name: Ligandrol (LGD-4033)
Brand: Master Pharma
SKU: SARM-LIGA-MAS-004
Price: 65.00 EUR
Availability: InStock

Master Pharma Ligandrol LGD-4033 is a selective androgen receptor modulator supplied as 10 mg oral tablets — 60 per blister — engineered for users who integrate structured lab monitoring into every phase of a SARM protocol. Each production lot clears two independent analytical checkpoints: HPLC active-content verification against a traceable reference standard, with LAL endotoxin quantification recorded on the lot-specific Certificate of Analysis shipped with every order.

€65.00Free shipping on orders over €300

In stock

Ships within 48 h Lab-tested batch

Precision 10 mg unit dose supports step-down adjustments when mid-cycle bloodwork flags HDL decline
60-tablet count aligns with a full monitoring-anchored 8-week protocol including baseline and post-cycle draw windows
Lot-specific HPLC Certificate of Analysis confirms active-content accuracy — critical when correlating dose to bloodwork response
LAL endotoxin clearance recorded per batch, not per brand-level attestation
Non-methylated oral SARM profile associated with lower hepatic enzyme stress versus alkylated oral androgens
Single active ingredient architecture eliminates multi-compound variables when interpreting lipid and hormone panel changes
Master Pharma EU GMP manufacturing site compliance provides auditable environmental and process controls at batch level

Phase	Dosage	Monitoring Note
Pre-cycle (7 days before)	0 mg — baseline labs only	Collect testosterone, LH, FSH, HDL, LDL, ALT, AST
Weeks 1–2 (ramp)	5 mg/day (half tablet)	Allow receptor adaptation before mid-range dosing
Weeks 3–8 (working phase)	10 mg/day (1 tablet)	Mid-cycle lipid + hormone panel at week 4–5
Week 8 (final week)	10 mg/day, last dose end of week	Schedule post-cycle draw for 4–6 weeks after final tablet
PCT / Recovery	Per PCT protocol	Confirm LH, FSH, HDL recovery before declaring cycle closed

Key takeaways

Draw baseline testosterone, LH, HDL and ALT before your first tablet.
Schedule a mid-cycle lipid panel at weeks four to five without exception.
Confirm LH and FSH recovery via post-cycle bloodwork four to six weeks after last dose.
Use the 10 mg tablet format to adjust dose if mid-cycle labs flag HDL suppression.
Verify every batch via Master Pharma's lot-specific HPLC Certificate of Analysis.

What Lab Work Actually Governs a Responsible LGD-4033 Cycle

Ligandrol (LGD-4033) is an investigational non-steroidal SARM that selectively activates androgen receptors in skeletal muscle and bone — and its clinical fingerprint on bloodwork markers makes pre-cycle, mid-cycle, and post-cycle laboratory panels an operational necessity rather than optional due diligence. Three biomarker categories define cycle safety: sex hormone axis (total testosterone, LH, FSH), lipid panel (HDL, LDL, triglycerides), and hepatic stress indicators (ALT, AST). Running LGD-4033 without baseline values in all three categories removes the ability to quantify suppression depth, interpret lipid shifts, or attribute any liver enzyme change to the compound rather than confounding variables.

Bloodwork Timelines: Before, During, and After

A structured monitoring protocol maps to three fixed draw points. The pre-cycle panel — collected at minimum 7 days before first dose — establishes your individual baseline; published Phase I data (Basaria et al., 2013) recorded dose-dependent testosterone suppression, meaning your personal starting LH and FSH values determine how much signal you lose by week four. A mid-cycle draw at weeks 4–5 lets you compare HDL trajectory against baseline: HDL suppression on LGD-4033 is consistently reported in the 20–30% range via lipid panels in controlled research settings, and users whose HDL drops below 35 mg/dL warrant protocol reassessment. Compared to a no-monitoring approach, mid-cycle labs allow dose adjustment before suppression becomes clinically significant. The post-cycle draw at 4–6 weeks after the last tablet confirms hormonal axis recovery — LH and FSH returning toward pre-cycle values signal that PCT is achieving its intended endpoint.

Hepatic and Lipid Markers: What to Track and Why

LGD-4033 carries a lower hepatotoxic signal than methylated oral anabolic steroids; ALT elevations in Phase I subjects remained within the moderate range. Nonetheless, ALT and AST should anchor every panel because they provide the only objective window into hepatic stress. Master Pharma's lot-specific Certificate of Analysis — generated from each batch's own HPLC run — confirms that what enters your protocol is the declared 10 mg of LGD-4033, not a concentration error that could distort dose-response and confound your bloodwork interpretation. The 60-tablet count supports a full monitoring-anchored cycle: baseline draw, 8-week run with a mid-cycle panel, then post-cycle recovery assessment — all within a single purchase without mid-cycle restocking.

Usage

Order your pre-cycle lab panel first.: Before opening the blister, arrange a draw for total testosterone, LH, FSH, SHBG, HDL, LDL, ALT, and AST. Do not begin dosing until results are in hand and reviewed.
Record your baseline numbers.: Log every value with the draw date — this reference set is the only meaningful benchmark against which mid-cycle and post-cycle panels can be interpreted.
Take one tablet (10 mg) orally each morning: with water, at a consistent time relative to meals. Consistent timing stabilises plasma levels given LGD-4033's extended half-life.
Book your mid-cycle draw at day 28–35.: The lipid panel is the primary target; an HDL drop exceeding 30% from baseline warrants a dosing review. Liver enzymes (ALT/AST) serve as a secondary hepatic checkpoint.
Complete the 8-week protocol and stop cleanly.: Initiate your chosen PCT regimen the day after the last tablet and schedule a post-cycle blood draw 4–6 weeks into PCT to confirm hormonal axis recovery.
File your Certificate of Analysis alongside your lab results.: The HPLC active-content figure on your Master Pharma batch CoA provides the dose-verification anchor that makes bloodwork correlation scientifically meaningful.

Warnings

Contraindications:

Not intended for individuals under 21, those with pre-existing cardiovascular conditions, diagnosed hepatic impairment, or active hormonal therapy. Women should avoid LGD-4033 due to androgenic activity risk.

Side Effects:

Testosterone suppression is the primary adverse effect — quantifiable via LH and FSH panels by week four. Lipid profile shifts (particularly HDL reduction) are reported across user data and Phase I trial observations. Fatigue and mild mood changes may accompany hormonal suppression in sensitive individuals.

Monitoring:

Pre-cycle, mid-cycle (week 4–5), and post-cycle bloodwork is not optional for responsible use. Lipid panels, hepatic enzyme panels, and sex hormone axes are the three mandatory monitoring categories. Mid-cycle results should drive dose continuation or adjustment decisions.

PCT:

Post-cycle therapy targeting LH/FSH recovery is required after any LGD-4033 cycle. Standard SERM-based PCT (e.g., Nolvadex or Clomid) is initiated the day after the last dose. Bloodwork at 4–6 weeks post-PCT confirms whether hormonal axis recovery is complete before considering any subsequent cycle.

Frequently asked questions

What specific blood tests should I run before starting an LGD-4033 cycle?: Run a full hormonal baseline: total testosterone, LH, FSH, SHBG, and estradiol. Add a lipid panel (HDL, LDL, triglycerides) and a hepatic enzyme panel (ALT, AST, bilirubin). These six categories provide the reference values needed to interpret every subsequent mid-cycle and post-cycle draw against your own physiology rather than population averages.
How much does HDL typically drop during an LGD-4033 cycle and when does it recover?: Clinical and user-reported data consistently show HDL suppression in the 20–30% range on LGD-4033, detectable by week 3–4 of dosing. Recovery typically begins within 4–6 weeks after the final dose, though the timeline depends on cycle length and individual lipid metabolism. A mid-cycle lipid panel at week 4 provides the earliest actionable signal.
Is LGD-4033 hepatotoxic, and do I need to monitor liver enzymes during a cycle?: LGD-4033 is not a methylated compound and shows a substantially lower hepatotoxic profile compared to 17-alpha-alkylated oral steroids. However, Phase I trial data (Basaria et al., 2013) did record mild transient ALT fluctuations in some subjects. Monitoring ALT and AST at baseline and mid-cycle remains the only objective method to confirm your individual hepatic response.
Why choose 10mg/tab for a lab-monitored LGD-4033 cycle rather than a higher concentration tablet?: The 10 mg tablet is the entry-level concentration in this product group, giving you precise dose control at the 5 mg (half-tablet) and 10 mg increments most commonly used during monitored protocols. When bloodwork signals mid-cycle adjustment — such as a significant HDL drop — a lower unit dose lets you step down without switching products.
How should I store Master Pharma Ligandrol 10mg tablets, and does storage affect dose accuracy?: Store tablets at room temperature (15–25 °C), away from direct light and humidity. Blistered tablet formats are inherently more stable than open-bottle storage. Master Pharma's HPLC-verified active-content data applies to properly stored units; temperature or humidity excursions can degrade potency and introduce variance that invalidates dose-tracking against your bloodwork timeline. (2) angle_used

Manufacturer

Master Pharma's product portfolio spans three distinct lines — peptide injectables, oral SARMs/research compounds, and ancillary support agents — and the analytical release framework governing each line is identical in its minimum requirements: HPLC active-content confirmation and LAL endotoxin quantification, both recorded lot-specifically on the Certificate of Analysis dispatched with every order. For the Ligandrol 10 mg/tab SKU within the oral SARM line, this means the HPLC figure on your CoA reflects the batch number printed on your packaging — not a pooled result, not a reference batch from a prior production run. EU GMP site compliance underpins the environmental and procedural controls that make those analytical figures reproducible across successive production years.

Product details

Brand	Master Pharma
Active ingredient	ligandrol
Also known as	Ligandrol (LGD-4033), Master Pharma Ligandrol (LGD-4033)
Strength	10 mg
Form	Tabletten
Pack size	60 pieces
Item number	SARM-LIGA-MAS-004

Reviews

No reviews yet. Be the first to review this product.

Write a review

Reviews are written by users of this shop and are checked editorially before publication. Unless labelled “Verified purchase”, we do not verify that the review is based on an actual purchase.

Similar products

Ligandrol 10mg/tab 60 Tablets by Elbrus Pharmaceuticals

Lab Tested

Ligandrol 10mg/tab 60 Tabletten by Elbrus Pharmaceuticals

Ligandrol (LGD-4033) is a high-affinity selective androgen receptor modulator supplied by Elbrus Pharmaceuticals in 10 mg oral tablets, formulated to support lean muscle accrual and progressive strength development across a structured bulk. Sixty tablets at 10 mg each provide a full six weeks of uninterrupted supply at the standard daily dose, with no splitting required for accurate dosing. Every production lot clears mandatory finished-product HPLC potency verification and LAL endotoxin screening before release — analytical outcome confirmation, not merely process documentation.

€70.00

Ligandrol 15mg/tab 50 Tablets by Rich Piana 5% Nutrition

HPLC Verified

Ligandrol 15mg/tab 50 Tabletten by Rich Piana 5% Nutrition

Rich Piana 5% Nutrition Ligandrol delivers LGD-4033 at a clinically relevant 15 mg per tablet — the highest concentration in this format — engineered specifically to support structured 8-week cycle protocols with clear dose-range checkpoints and defined time-off planning. Each of the 50 tablets is precisely portioned so researchers can execute conservative entry doses, standard maintenance phases, and planned cessation windows without splitting or approximating. Batch potency is confirmed through HPLC (High-Performance Liquid Chromatography) quantitative analysis; every unit reaching distribution carries verified label accuracy to analytical tolerance.

€65.00

Batch Tested

Ligandrol 10mg/tab 30 Tablets by Vital Research

Ligandrol (LGD-4033) is a selective androgen receptor modulator supplied here as 10 mg oral tablets, formulated as a precision building block for goal-specific SARM stacks — whether you are running a lean-bulk protocol paired with RAD-140 or evaluating it against a cut-phase Ostarine/Cardarine arrangement. Each 30-tablet blister is sized to anchor a structured stack cycle with consistent per-tablet delivery. Release criteria at Vital Research are enforced through two independent analytical gates: HPLC quantification of active LGD-4033 content and LAL endotoxin screening — both required before any blister unit enters distribution.

€45.00

Stack it with

Pairs well with these products.

High Concentration

Quant-Equipoise 300mg/ml 10ml Vial by Beligas Pharmaceuticals

Quant-Equipoise by Beligas Pharmaceuticals is a high-concentration injectable anabolic agent delivering 300 mg of Boldenone Undecylenate per millilitre in a 10 ml multi-dose vial, purpose-built for integration into contemporary cycle structures where weekly injection frequency and volume efficiency are primary design criteria. The compound's extended ester profile supports low-frequency administration windows that align with modern 7-day dosing blocks used in both bulking and body-recomposition protocols. Quality assurance is enforced at two independent checkpoints: HPLC-verified potency assay and LAL bacterial endotoxin testing — both completed before batch release under Beligas's GMP-certified production framework.

€47.00

Bolden-250 250mg/ml 10x1ml Ampoules by BM Pharmaceuticals

Long-Acting Formula

Bolden-250 250mg/ml 10x1ml Ampullen by BM Pharmaceuticals

Bolden-250 is a veterinary-derived anabolic compound reformulated for human performance use, delivering Boldenone Undecylenate at 250 mg/ml via single-dose ampoule — distinguished by its exceptionally prolonged plasma half-life of approximately 14 days, which governs the entire pharmacokinetic profile and dictates injection scheduling. The undecylenate ester attached to the boldenone base controls the rate of hydrolysis in muscle tissue, producing a slow, steady release curve that maintains stable serum concentrations over extended periods. Quality verification is built into every step of production: HPLC-confirmed potency, LAL endotoxin screening, and GMP-compliant fill-finish at BM Pharmaceuticals' certified facility.

€48.00

Brand Quality

EquiTrex 350mg/ml 10ml Vial by Concentrex Labs

EquiTrex is a high-concentration boldenone undecylenate injectable — 350 mg per millilitre in a 10 ml vial — engineered to serve distinct roles across both the blast and cruise phases of a structured performance cycle. Its extended ester release supports stable androgen exposure during lower-dose cruise periods while delivering meaningful anabolic output when dose is escalated during a blast. Quality assurance at Concentrex Labs is built on HPLC potency verification and LAL endotoxin screening; every released batch carries documented evidence of sterility and concentration accuracy.

€52.00

Pro Choice

EQ 300 300mg/ml 10ml Vial by Dragon-Pharma

Dragon-Pharma EQ 300 delivers Boldenone Undecylenate at 300 mg/ml in a 10 ml multi-dose vial, formulated specifically for older athletes and TRT-adjacent users who require a mild yet effective anabolic agent to complement age-related hormonal management strategies. Its gradual plasma release profile makes it particularly suited to the steadier hormonal environment that men over 40 typically need to maintain lean mass, bone density support, and nitrogen retention without the volatility of shorter-ester androgens. Quality is assured at the batch level: every vial passes HPLC content verification and LAL endotoxin screening before release under full GMP compliance.

€44.00